Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 10/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.35 |
| ▸ | GCGR | P47871 | 1/20 | 0.33 |
| ▸ | KIT | P10721 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2988009 | 0.87 | LMNA (0.36) | LMNACA12CA1CA2CA9 | |
| SCHEMBL2987950 | 0.84 | BRAF (0.36) | LMNABRAFDHODH | |
| SCHEMBL2998731 | 0.80 | BRAF (0.46) | BRAFKIT | |
| SCHEMBL17530722 | 0.79 | BRAF (0.37) | BRAF | |
| SCHEMBL15455062 | 0.79 | BRAF (0.36) | LMNACA12CA1CA2CA9 | |
| SCHEMBL2994049 | 0.79 | BRAF (0.35) | BRAFDHODH | |
| SCHEMBL17332223 | 0.79 | BRAF (0.39) | CA12CA1CA2CA9BRAF | |
| SCHEMBL1935490 | 0.79 | CA12 (0.38) | LMNACA12CA1CA2CA9 | |
| SCHEMBL2994080 | 0.78 | BRAF (0.38) | BRAF | |
| SCHEMBL2991900 | 0.78 | BRAF (0.39) | BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536338-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-09-17 | — | — | US | disclosed |
| US-8293909-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-23 | — | — | US | disclosed |
| US-20120232099-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2012-09-13 | — | — | US | disclosed |
| US-8198449-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-06-12 | — | — | US | disclosed |
| US-20100184800-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2010-07-22 | — | — | US | disclosed |
| US-20100063068-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063068-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | LMNA 3141/4885CA12 1432/4885CA1 4156/4885 |
| US-20100184800-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | LMNA 3141/4885CA12 1432/4885CA1 4156/4885 |
| US-20120232099-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | LMNA 3141/4885CA12 1432/4885CA1 4156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.